Stay updated with breaking news from Biocelect Pty. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...
(RTTNews) - Novavax, Inc. (NVAX) announced that Nuvaxovid COVID-19 vaccine received expanded manufacturing and marketing approval in Japan to prev...
In Australia, Nuvaxovid™ is the first protein-based COVID-19 vaccine registered for use as a booster regardless of previous vaccine historyGAITHER...
Maryland-based Novavax Inc. recently announced the first doses of its protein-based COVID-19 vaccine would be available to New Zealanders beginning this week. As of March 14, 2022, the two-dose Nuvaxovid™ COVID-19 Vaccine (adjuvanted) for active immunization to prevent COVID-19 in individuals 18 years of age and older will be available throughout New Zealand.
The first dose of Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) was administered today in Australia during a press briefing by The Hon Greg Hunt MP, Federal Minister for Health and Aged Care.